NIMBEX Drug Patent Profile

When do Nimbex patents expire, and when can generic versions of Nimbex launch?

Nimbex is a drug marketed by Abbvie and is included in one NDA.

The generic ingredient in NIMBEX is cisatracurium besylate. There are nine drug master file entries for this compound. Sixteen suppliers are listed for this compound. Additional details are available on the cisatracurium besylate profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Nimbex

A generic version of NIMBEX was approved as cisatracurium besylate by SANDOZ INC on February 3^rd, 2012.

Summary for NIMBEX

US Patents:	0
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	63
Clinical Trials:	13
Patent Applications:	715
Drug Prices:	Drug price information for NIMBEX
What excipients (inactive ingredients) are in NIMBEX?	NIMBEX excipients list
DailyMed Link:	NIMBEX at DailyMed

See drug prices for NIMBEX

Recent Clinical Trials for NIMBEX

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Mahidol University	Phase 4
Makassed General Hospital	N/A
Assiut University	Phase 2/Phase 3

See all NIMBEX clinical trials

US Patents and Regulatory Information for NIMBEX

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Abbvie	NIMBEX	cisatracurium besylate	INJECTABLE;INJECTION	020551-001	Dec 15, 1995		DISCN	Yes	No
Abbvie	NIMBEX PRESERVATIVE FREE	cisatracurium besylate	INJECTABLE;INJECTION	020551-003	Dec 15, 1995		DISCN	Yes	No
Abbvie	NIMBEX PRESERVATIVE FREE	cisatracurium besylate	INJECTABLE;INJECTION	020551-002	Dec 15, 1995		DISCN	Yes	No

Expired US Patents for NIMBEX

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Abbvie	NIMBEX	cisatracurium besylate	INJECTABLE;INJECTION	020551-001	Dec 15, 1995	4,179,507
Abbvie	NIMBEX	cisatracurium besylate	INJECTABLE;INJECTION	020551-001	Dec 15, 1995	5,453,510

International Patents for NIMBEX

See the table below for patents covering NIMBEX around the world.

Country	Patent Number	Title	Estimated Expiration
Finland	61485
New Zealand	238964	GEOMETRICALLY AND OPTICALLY PURE 1R-CIS,1'R-CIS ATRACURIUM SALTS, PREPARATION AND PHARMACEUTICAL COMPOSITIONS THEREOF
Japan	3462165
France	2665701	AGENTS DE BLOCAGE NEUROMUSCULAIRE.
Mexico	9203220	AGENTES DE BLOQUEO NEUROMUSCULAR.

NIMBEX Market Analysis and Financial Projection Experimental

Market Dynamics and Financial Trajectory for NIMBEX (Cisatracurium Besylate)

Introduction to NIMBEX

NIMBEX, or cisatracurium besylate, is a nondepolarizing skeletal muscle relaxant used in surgical settings to provide muscle relaxation. It is administered intravenously and is known for its stable cardiovascular profile and lack of histamine release, which reduces the risk of allergic reactions.

Market Size and Growth

The global neuromuscular blockade drugs market, which includes NIMBEX, is projected to experience significant growth. As of 2023, the market size was valued at USD 5.23 billion and is expected to reach USD 7.44 billion by 2031, with a Compound Annual Growth Rate (CAGR) of 4.50% during the forecast period of 2024 to 2031[1].

Drivers of Market Growth

Increasing Surgical Procedures

The demand for neuromuscular blockade drugs like NIMBEX is driven by the increasing number of surgical procedures worldwide. Surgical fields such as orthopedics, cardiovascular surgery, and oncology are seeing a rise in procedures, which in turn increases the need for muscle relaxants to enhance surgical outcomes and reduce complications[1].

Rising Geriatric Population

The growing geriatric population is another significant driver. Older patients often require more surgical interventions, and neuromuscular blockade drugs are crucial in these cases to ensure safe and effective surgical procedures[1].

Advancements in Healthcare Infrastructure

Improvements in healthcare infrastructure, particularly in emerging economies, are also driving the market. The introduction of novel neuromuscular blockade drugs and the growing focus on research and development to enhance safety and efficacy further contribute to market growth[1].

Market Segmentation

By Type

NIMBEX falls under the category of nondepolarizing neuromuscular blocking agents. This segment is expected to see substantial growth due to the preference for nondepolarizing agents in surgical settings due to their stable pharmacological profiles and lower risk of adverse events compared to depolarizing agents[1].

By End-Users

Hospitals are the primary end-users of NIMBEX, followed by specialty clinics and homecare settings. The well-established healthcare infrastructure in regions like North America, where hospitals are major consumers, contributes significantly to the market[1].

By Distribution Channel

NIMBEX is primarily distributed through hospital pharmacies, with retail pharmacies and online pharmacies also playing a role. The dominance of hospital pharmacies in the distribution channel is due to the critical nature of the drug and the need for immediate availability in surgical settings[1].

Regional Analysis

North America

North America is expected to dominate the market for neuromuscular blockade drugs, including NIMBEX, due to the region's strong focus on research and development, well-established healthcare infrastructure, and the presence of leading pharmaceutical companies and research institutions[1].

Other Regions

Other regions, such as Europe and Asia-Pacific, also show significant growth potential. In pharmerging countries like China, there is an increasing trend towards earlier access to newer medicines, including neuromuscular blockade drugs, which is expected to drive market growth[3].

Adverse Events and Safety Profile

While NIMBEX is generally well-tolerated, adverse event reports are crucial for understanding its safety profile. According to a study analyzing reports from the FDA's Adverse Event Reporting System (FAERS), cisatracurium, the active ingredient in NIMBEX, had a lower incidence of adverse events compared to other neuromuscular blocking agents. The study highlighted that cisatracurium accounted for 10.22% of the reports, with the majority related to its pharmacological effects rather than severe adverse reactions[4].

Financial Performance and Outlook

Revenue Growth

The revenue growth for NIMBEX is aligned with the overall growth of the neuromuscular blockade drugs market. As the market expands, driven by increasing surgical procedures and advancements in healthcare, the revenue from NIMBEX is expected to increase. The CAGR of 4.50% for the global market indicates a steady and predictable financial trajectory for NIMBEX[1].

Competitive Landscape

The market for neuromuscular blockade drugs is competitive, with several major players. However, NIMBEX's stable cardiovascular profile and lack of histamine release make it a preferred choice in many surgical settings, contributing to its financial performance. The presence of other nondepolarizing agents like rocuronium, atracurium, and vecuronium also influences the market dynamics, but NIMBEX's unique characteristics help it maintain a significant market share[1].

Regulatory Framework

The regulatory environment plays a crucial role in the financial trajectory of NIMBEX. Regulatory approvals and compliance with safety standards are essential for maintaining market presence. The FDA's oversight and the need for continuous monitoring of adverse events ensure that NIMBEX meets the highest safety and efficacy standards, which in turn supports its financial performance[5].

Key Takeaways

• Market Growth: The global neuromuscular blockade drugs market, including NIMBEX, is projected to grow at a CAGR of 4.50% from 2024 to 2031.
• Drivers: Increasing surgical procedures, rising geriatric population, and advancements in healthcare infrastructure drive the market.
• Segmentation: NIMBEX falls under nondepolarizing agents, with hospitals being the primary end-users.
• Regional Dominance: North America is expected to dominate the market due to its strong healthcare infrastructure and research focus.
• Safety Profile: NIMBEX has a favorable safety profile with a lower incidence of adverse events compared to other agents.
• Financial Outlook: The revenue growth for NIMBEX is steady and predictable, aligned with the overall market growth.

FAQs

What is the projected market size for neuromuscular blockade drugs by 2031?

The global neuromuscular blockade drugs market is projected to reach USD 7.44 billion by 2031[1].

What are the primary drivers of the market growth for NIMBEX?

The primary drivers include increasing surgical procedures, a rising geriatric population, and advancements in healthcare infrastructure[1].

Which region is expected to dominate the market for NIMBEX?

North America is expected to dominate the market due to its well-established healthcare infrastructure and strong focus on research and development[1].

What is the safety profile of NIMBEX compared to other neuromuscular blocking agents?

NIMBEX has a favorable safety profile with a lower incidence of adverse events compared to other agents, such as rocuronium and atracurium[4].

How does the regulatory framework impact the financial performance of NIMBEX?

The regulatory framework ensures that NIMBEX meets the highest safety and efficacy standards, which supports its financial performance by maintaining market presence and compliance[5].

Sources

1. Data Bridge Market Research: Global Neuromuscular Blockade Drugs Market Size, Demand & Research Report.
2. Perrigo Investor Day Slides: Corporate Overview 2011.
3. Global Foresight Group: The Global Use of Medicines 2022 - Outlook to 2026.
4. Frontiers in Pharmacology: Adverse events related to neuromuscular blocking agents.
5. FDA Label: Nimbex (cisatracurium besylate) injection label.